Ongoing Clinical Trials for Ovarian Epithelial Cancer Stage III
Currently, there is 1 ongoing clinical trial for patients with Stage III ovarian epithelial cancer. This trial focuses on maintenance treatment using a combination of targeted therapies for patients whose tumors show specific genetic characteristics. The trial is being conducted in Italy and involves medicines that work by blocking cancer cell repair mechanisms and cutting off the tumor’s blood supply.
Clinical trial locations
Study on the Effectiveness of Olaparib and Bevacizumab for Maintenance Treatment in Patients with HRD-Positive Ovarian Cancer
This clinical trial investigates a maintenance treatment approach for patients with advanced, high-grade epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer. The study specifically targets patients whose tumors have a particular genetic characteristic called homologous recombination deficiency (HRD), which affects how cancer cells repair damaged DNA.
Main inclusion criteria:
- You must be at least 18 years old
- Have a new diagnosis of high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer
- Have advanced disease classified as FIGO stage III-IV
- Be suitable to receive platinum-taxane chemotherapy combined with bevacizumab
- Have normal organ and bone marrow function
- Have normal or controlled blood pressure (systolic ≤ 140 mmHg and/or diastolic ≤ 90 mmHg)
- Have an ECOG performance status of 0-1, meaning you are fully active or have some symptoms but can carry out light work
- Have a life expectancy of at least 16 weeks
- Provide tumor samples for testing that show HRD-positive status
Main exclusion criteria:
- Patients without confirmed advanced, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Patients not eligible to start chemotherapy with bevacizumab
- Patients whose tumor samples do not show positive HRD status on the Myriad Mychoice CDxPlus test
- Patients who do not achieve a complete or partial response after initial platinum-based chemotherapy plus bevacizumab
- Patients whose tumors do not have a BRCA1-2 mutation as determined by testing
- Patients who do not meet other specific eligibility criteria for treatment with olaparib and bevacizumab
Focus and goal of the trial:
The study aims to confirm how well the combination of olaparib and bevacizumab works as maintenance therapy for patients who have already completed standard chemotherapy and shown a positive response. Maintenance therapy means using treatment to help prevent the cancer from returning after the initial treatment has been successful. The trial will monitor how patients respond to this combination over time and gather information about both effectiveness and safety.
Participants will first receive standard chemotherapy with a platinum-based drug and bevacizumab. After completing this initial treatment, patients who show a complete or partial response and have HRD-positive tumors will begin taking olaparib tablets along with bevacizumab infusions. The study will track patient outcomes and any side effects that occur during treatment. The trial is expected to continue until June 2026.
Investigational drugs:
Olaparib is a medication classified as a PARP inhibitor. It works by blocking a protein called PARP that helps cancer cells repair their damaged DNA. When PARP is blocked, cancer cells cannot fix themselves and eventually die. In this trial, olaparib is taken orally as tablets in doses of either 150 mg or 100 mg, as prescribed by your healthcare provider. It is used as maintenance treatment to help keep the cancer from coming back.
Bevacizumab is a medication known as an angiogenesis inhibitor or monoclonal antibody. It works by blocking a protein called VEGF, which helps tumors grow new blood vessels. By blocking VEGF, bevacizumab cuts off the blood supply that the tumor needs to grow and spread. In this trial, bevacizumab is given through an intravenous infusion and is used alongside olaparib as part of the maintenance treatment strategy.
Summary
Currently, there is one active clinical trial available for patients with Stage III ovarian epithelial cancer. This trial is located in Italy and focuses on a specific subset of patients whose tumors show HRD-positive status, particularly those with BRCA1-2 mutations. The study represents an important investigation into maintenance therapy using two targeted medicines that work through different mechanisms: one blocking DNA repair in cancer cells and the other cutting off the tumor’s blood supply.
The trial specifically targets patients who have responded well to initial chemotherapy, aiming to extend the period before cancer returns. This approach reflects current understanding that maintenance treatment can be beneficial for carefully selected patients with specific genetic characteristics in their tumors. Patients interested in this trial should discuss with their oncologist whether they meet the specific eligibility criteria, particularly regarding HRD status and response to initial treatment.
